Intangible Assets (Details 2) (USD $)	6 Months Ended		0 Months Ended	6 Months Ended	0 Months Ended		1 Months Ended	3 Months Ended					1 Months Ended		6 Months Ended	1 Months Ended	6 Months Ended		6 Months Ended		6 Months Ended		6 Months Ended
	Jun. 30, 2013 item	Dec. 31, 2012	May 28, 2010 Auralis Limited item	Jun. 30, 2013 Cinryze item	Apr. 09, 2012 Vancocin item	Dec. 14, 2011 Vancocin	Jun. 30, 2012 Vancocin item	Mar. 31, 2013 Vancocin	Jun. 30, 2013 Vancocin	Dec. 31, 2012 Vancocin	Sep. 30, 2012 Vancocin	Mar. 31, 2012 Vancocin	Sep. 30, 2011 Buccolam Minimum	Sep. 30, 2011 Buccolam Maximum	Jun. 30, 2013 Product Rights Auralis Limited	Oct. 31, 2008 Product Rights Cinryze	Jun. 30, 2013 Product Rights Cinryze	Dec. 31, 2012 Product Rights Cinryze	Jun. 30, 2013 Product Rights Buccolam	Dec. 31, 2012 Product Rights Buccolam	Jun. 30, 2013 Product Rights Plenadren	Dec. 31, 2012 Product Rights Plenadren	Jun. 30, 2013 Contract Rights Auralis Limited	Dec. 31, 2012 Contract Rights Auralis Limited
Finite-Lived Intangible Assets Disclosures
Exclusivity period for orphan drug																7 years
Carrying amount of intangible asset	$ 494,392,000	$ 617,539,000						$ 7,400,000	$ 6,913,000	$ 113,326,000							$ 423,200,000	$ 433,606,000	$ 5,049,000	$ 5,690,000	$ 53,228,000	$ 58,088,000	$ 6,016,000	$ 6,829,000
Useful life of acquired intangible assets beyond the orphan exclusivity period																	18 years
Useful life of acquired intangible assets beyond the data protection period for biosimilar versions																	13 years
Number of patients treated by a specific product				4,600
Number of people thought to be affected by HAE but not yet diagnosed				10,000
Maximum period for non-licensing of a biosimilar after first licensing of reference biologic	12 years
Number of C1 inhibitors who received approval for prophylaxis	1
Amount by which sum of undiscounted cash flows exceeded carrying amount											34,000,000	210,000,000
Useful life of acquired intangible assets				25 years											10 years		25 years		10 years		10 years		12 years
Remaining estimated useful life of intangible asset								3 years 9 months
Remaining estimated useful life of intangible asset before cash flow projections								16 years 9 months
Additional years of exclusivity not qualified						3 years
Number of ANDAs approved					3		4
Age of children and adolescents for the purpose of being eligible for treatment													3 months	18 years
Number of marketed products			1
Number of development assets			1
Non-cash asset impairments	$ 104,245,000							$ 104,200,000